DCF — MASSACHUSETTS EYE AND EAR INFIRMARY
Enterprise Value: $-233.4M
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
$-233.4M
Enterprise Value
$-78.1M
PV of Cash Flows
$-155.3M
PV of Terminal Value
$-250.1M
Terminal Value
10.0%
WACC
2.5%
Terminal Growth
Cash Flow Projections
PROJ| Year | Revenue | EBITDA | Margin | FCF | PV(FCF) |
|---|---|---|---|---|---|
| Year 1 | $271.8M | $-12.2M | -5.0% | $-23.7M | $-21.6M |
| Year 2 | $280.0M | $-9.8M | -4.0% | $-21.6M | $-17.9M |
| Year 3 | $288.4M | $-7.2M | -3.0% | $-19.4M | $-14.6M |
| Year 4 | $297.0M | $-5.9M | -2.0% | $-18.5M | $-12.6M |
| Year 5 | $305.9M | $-5.4M | -2.0% | $-18.3M | $-11.4M |
Interpretation
INTAt a WACC of 10.0% and terminal growth of 2.5%, enterprise value is $-233.4M. Terminal value accounts for 0% of total EV — consider sensitivity to terminal assumptions.
Next steps: Check the LBO model to see equity returns at this entry price, or the EBITDA bridge to model value creation levers.
Assumptions
ASSMrevenue base$263.9M
revenue growth rates[0.03, 0.03, 0.03, 0.03, 0.03]
ebitda margin base-0.050000000757904825
ebitda margin improvement bps[50, 100, 100, 50, 25]
capex pct revenue0.04
nwc pct revenue0.08
tax rate0.25
projection years5